CompletedPhase 1NCT04374877
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Studying Clear cell renal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Coherus Oncology, Inc.
- Principal Investigator
- Koho Iizuka, MDCoherus BioSciences
- Intervention
- CHS-388(drug)
- Enrollment
- 145 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2025
Study locations (23)
- City of Hope, Duarte, California, United States
- University of Southern California (USC) - Norris Comprehensive Cancer Center, Los Angeles, California, United States
- UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- University of Miami Leonard M. Miller School of Medicine (UMMSM), Miami, Florida, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Health System (UMHS), Ann Arbor, Michigan, United States
- Washington University School of Medicine - St. Louis, St Louis, Missouri, United States
- Roswell Park, Buffalo, New York, United States
- Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- University of Oklahoma Health Sciences Center (OUHSC) - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI)), Pittsburgh, Pennsylvania, United States
- Vanderbilt University Medical Center (VUMC), Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
- +8 more locations on ClinicalTrials.gov
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04374877 on ClinicalTrials.govOther trials for Clear cell renal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07128680Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center
- RECRUITINGPHASE2NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCKarie Runcie
- RECRUITINGPHASE2NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Brian Rini
- RECRUITINGPHASE2NCT07469683An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaYonsei University
- RECRUITINGPHASE1, PHASE2NCT07227415A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPfizer
- RECRUITINGPHASE1, PHASE2NCT07551349Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaBeijing Biotech
- RECRUITINGPHASE2NCT07223541Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaUniversity of Oklahoma